Cargando…

Immune Checkpoint Inhibitors and Opioids in Patients with Solid Tumours: Is Their Association Safe? A Systematic Literature Review

Background: Immune checkpoint inhibitors (ICIs) represent one of the most effective treatments for patients with cancer. As their activity relies on host immune system reactivity, the role of concomitant medications such as corticosteroids and antibiotics has been extensively evaluated. Preclinical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cani, Massimiliano, Bironzo, Paolo, Garetto, Ferdinando, Buffoni, Lucio, Cotogni, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818864/ https://www.ncbi.nlm.nih.gov/pubmed/36611575 http://dx.doi.org/10.3390/healthcare11010116

Ejemplares similares

Is there any place for immune-checkpoint inhibitors in the treatment algorithm of fusion-driven non-small cell lung cancer?—a literature review
por: Leone, Gianmarco, et al.
Publicado: (2020)

Targeting KRAS in NSCLC: Old Failures and New Options for “Non-G12c” Patients
por: Jacobs, Francesca, et al.
Publicado: (2021)

Immune Thrombocytopenia Induced by Immune Checkpoint Inhibitors in Solid Cancer: Case Report and Literature Review
por: Liu, Xiaolin, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors in Patients With Cancer and Infection by Hepatitis B or C Virus: A Perspective Through the Results of a European Survey
por: Tagliamento, Marco, et al.
Publicado: (2022)

Hyperprogressive Disease (HPD) in Solid Tumours Receiving Immune Checkpoint Inhibitors in a Real-World Setting
por: Kanjanapan, Yada, et al.
Publicado: (2023)

Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
por: Sun, Qian, et al.
Publicado: (2023)

Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity
por: Madan, Ravi A, et al.
Publicado: (2012)

Clinical utility of tumour mutational burden on efficacy of immune checkpoint inhibitors in malignant solid tumours: protocol for a systematic review and meta-analysis
por: Xiang, Xuemei, et al.
Publicado: (2022)

Infectious complications of immune checkpoint inhibitors in solid organ malignancies
por: Ross, Justine Abella, et al.
Publicado: (2021)

Increasing cure rates of solid tumors by immune checkpoint inhibitors
por: Ma, Weijie, et al.
Publicado: (2023)

Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
por: Ascierto, Paolo A., et al.
Publicado: (2017)

Immune checkpoint inhibitors in penile cancer
por: Buonerba, Carlo, et al.
Publicado: (2021)

Efficacy of Immune Checkpoint Inhibitors in Rare Tumours: A Systematic Review
por: Petrelli, Fausto, et al.
Publicado: (2021)

How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?
por: Denis, Morgane, et al.
Publicado: (2020)

Retreatment with immune checkpoint inhibitors in solid tumors: a systematic review
por: Yang, Kaili, et al.
Publicado: (2020)

Repurposing glucocorticoids as adjuvant reagents for immune checkpoint inhibitors in solid cancers
por: Yu, Yingyan
Publicado: (2021)

Immune checkpoint inhibitors for solid organ transplant recipients: clinical updates
por: Kawashima, Shun, et al.
Publicado: (2022)

ICU admission for solid cancer patients treated with immune checkpoint inhibitors
por: Toffart, Anne-Claire, et al.
Publicado: (2023)

Cytomegalovirus Infections in Patients Treated With Immune Checkpoint Inhibitors for Solid Malignancies
por: Anastasopoulou, Amalia, et al.
Publicado: (2023)

Repurposing drugs for solid tumor treatment: focus on immune checkpoint inhibitors
por: Liu, Qingxu, et al.
Publicado: (2023)

Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors
por: Ahn, Ryuhjin, et al.
Publicado: (2021)

Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma
por: Beug, Shawn T., et al.
Publicado: (2017)

Impact of opioid analgesics on the efficacy of immune checkpoint inhibitors in a lung cancer population
por: Yu, Xiaoyuan, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors in Melanoma and HIV Infection
por: Marra, Antonio, et al.
Publicado: (2017)

Management of parenteral nutrition in critically ill patients
por: Cotogni, Paolo
Publicado: (2017)

Culprits of PDAC resistance to gemcitabine and immune checkpoint inhibitor: Tumour microenvironment components
por: Hsu, Sheng-Kai, et al.
Publicado: (2022)

Prevalence of PRKDC mutations and association with response to immune checkpoint inhibitors in solid tumors
por: Chen, Yu, et al.
Publicado: (2020)

Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors
por: Zhang, Lei, et al.
Publicado: (2020)

Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Therapy Is Safe and Facilitates Treatment-free Intervals
por: Shapiro, Daniel D., et al.
Publicado: (2023)

Immune Checkpoints in Solid Organ Transplantation
por: Del Bello, Arnaud, et al.
Publicado: (2023)

The sexist behaviour of immune checkpoint inhibitors in cancer therapy?
por: Botticelli, Andrea, et al.
Publicado: (2017)

Opioids and immune checkpoint inhibitors differentially regulate a common immune network in triple-negative breast cancer
por: Scarpa, Joseph R., et al.
Publicado: (2023)

Neurologic Toxicity of Immune Checkpoint Inhibitors: A Review of Literature
por: Albarrán, Víctor, et al.
Publicado: (2022)

Inhibiting the inhibitors: Checkpoints blockade in solid tumors
por: Mavilio, Domenico, et al.
Publicado: (2013)

The Resistance Mechanisms of Checkpoint Inhibitors in Solid Tumors
por: Koustas, Evangelos, et al.
Publicado: (2020)

Treatment of Cutaneous Squamous Cell Carcinoma with Immune Checkpoint Inhibitors in Special Populations
por: Bossi, Paolo, et al.
Publicado: (2021)

Infection risk with PI3K-AKT-mTOR pathway inhibitors and immune checkpoint inhibitors in patients with advanced solid tumours in phase I clinical trials
por: Fujiwara, Yutaka, et al.
Publicado: (2020)

Immune checkpoint inhibitors
por: Hui, Enfu
Publicado: (2019)

Immune checkpoint inhibitors
por: Kroemer, Guido, et al.
Publicado: (2021)

How to Monitor Cardiac Complications of Immune Checkpoint Inhibitor Therapy
por: Spallarossa, Paolo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ob5uj3r982rnc1m66h9gmc9vv4